pharmaphorum Podcast

Artificial intelligence is now embedded in every stage of drug development, but the patients whose lives depend on those decisions are almost entirely absent from the design, governance, and oversight of these systems.

In a new pharmaphorum podcast, Nicole Raleigh speaks with Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC, as well as patient advocate, FDA Patient Representative, and founder of the Global Liver Institute and member of the Board of Advisors at PathAI.

Cryer discusses why patient inclusion is not the same as patient leadership, and why that distinction matters for drug development and AI governance.

You can listen to episode 285 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.

AION Labs is a venture studio built by a coalition of pharma heavyweights, tech giants, and leading investors to develop and integrate AI technologies to redefine drug discovery and development through the creation of new start-ups.

Gill discusses some great start-ups coming out of the AION Labs co-development model, what investors now expect of AI biotech companies, and the potential of AI in drug discovery and development for the good of human health.

You can listen to episode 284 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

At ESMO 2026, Taiho Oncology presented data from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (or NSCLC) harbouring epidermal growth factor receptor (or EGFR) exon 20 insertion mutations or other uncommon EGFR mutations and active central nervous system (or CNS) metastases.

During the Congress, pharmaphorum’s Nicole Raleigh invited Dr Harold Keer, chief medical officer at Taiho Oncology, as a guest on the podcast while he was on the ground in Madrid, Spain.

Dr Keer discusses the non-small cell lung cancer patient and treatment setting, as well as  improving the lives of patients with cancer, their families, and their caregivers. He also goes into detail on Taiho’s orally administered anti-cancer agents for various tumour types and an expanding pipeline of antibody-drug conjugate (or ADC) therapies.

Listen to the conversation and explore our updates from ESMO 2026 here.

As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast for a conversation on the updated long-term overall survival data from its Phase 1 trial of SYNC-T Therapy SV-102 in patients with metastatic prostate cancer.

Dr Link discusses SYNC-T, their investigational in situ personalised immunotherapy, as well as metastatic castration-resistant (or mCRPC) and metastatic hormone-sensitive (or mHSPC) disease, and the possible outcomes for patients going forward.

Listen to the conversation and keep up on ESMO26 updates here.

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

By 2030, 1.2 billion women worldwide will be menopausal or post-menopausal - many at the peak of their working lives. Yet, menopause remains largely absent from health system planning, despite growing evidence linking unmanaged symptoms to reduced productivity, absenteeism, and women leaving the workforce altogether.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Cecilia Caetano, vice president, global medical affairs and evidence generation lead in women’s health at Bayer, for a conversation on this overlooked, but increasingly urgent global health issue.

Caetano discusses the lack of innovation in women’s health and, critically, the lack of understanding of menopausal needs. She also explores the European landscape for menopause in comparison to the UK, as well as describing what ‘health system readiness’ looks like.

You can listen to episode 281 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*